{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:08:09Z","timestamp":1789844889977,"version":"4.0.1"},"reference-count":90,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institutes on Drug Abuse","doi-asserted-by":"crossref","award":["R01DA-050629"],"award-info":[{"award-number":["R01DA-050629"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,6,27]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>Methadone and buprenorphine\/naloxone are effective medications for people with opioid use disorder; however, interruptions in daily dosing are common and diminish the benefits of these medications. While clinical guidelines in most North American jurisdictions, including British Columbia (BC), recommend dose adjustment after treatment interruptions to varying levels of specificity, the evidence to support these recommendations is limited. We aim to estimate the comparative effectiveness of alternative dose adjustment strategies on subsequent overdose-related acute care visits and discontinuation of opioid agonist treatment in BC, Canada.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods and analysis<\/jats:title>\n<jats:p>Using a linkage of nine health administrative databases, we propose a population-level retrospective cohort study of adults aged 18 years or older in BC who initiated methadone or buprenorphine\/naloxone between 1 January 2010 and 31 December 2022. We will specify parallel hypothetical trials, known as target trials, for methadone interruptions of 1\u20133\u2009days, 4\u2009days and 5\u201314\u2009days, and buprenorphine\/naloxone interruptions of 1\u20135\u2009days and 6\u201314\u2009days. Following the index interruption, the primary outcomes are the time to overdose-related acute care visits and treatment discontinuation (interruptions lasting &gt;14\u2009days), with time to all-cause acute care visits as a secondary outcome. The intention-to-treat effect will be estimated using both propensity score and instrumental variable approaches. A range of sensitivity analyses will assess the robustness of our results, including cohort and timeline restriction, alternative definitions of exposure and outcome and alternative estimation strategies.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Ethics and dissemination<\/jats:title>\n<jats:p>The protocol, cohort creation and analysis plan have been classified and approved as a quality improvement initiative by Providence Health Care Research Institute and the Simon Fraser University Office of Research Ethics. All data are deidentified, securely stored and accessed in accordance with provincial privacy regulations. Results will be disseminated to local advocacy groups and decision-makers, national and international clinical guideline developers, presented at international conferences and published in peer-reviewed journals electronically and in print.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bmjopen-2024-098318","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T17:40:06Z","timestamp":1753292406000},"page":"e098318","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative effectiveness of missed dose protocols of opioid agonist treatment in British Columbia, Canada: protocol for a population-based target trial emulation"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-2118","authenticated-orcid":false,"given":"Momenul Haque","family":"Mondol","sequence":"first","affiliation":[{"name":"School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"},{"name":"University of Barishal, Barishal, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0968-722X","authenticated-orcid":false,"given":"Jeong Eun","family":"Min","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Kurz","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8469-7210","authenticated-orcid":false,"given":"Michelle","family":"Zanette","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-863X","authenticated-orcid":false,"given":"Md Belal","family":"Hossain","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paxton","family":"Bach","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2375-5006","authenticated-orcid":false,"given":"Paul","family":"Gustafson","sequence":"additional","affiliation":[{"name":"Department of Statistics, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Platt","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3726-5937","authenticated-orcid":false,"given":"Shaun","family":"Seaman","sequence":"additional","affiliation":[{"name":"MRC Biostatistics Unit, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Soc\u00edas","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-3718","authenticated-orcid":false,"given":"Bohdan","family":"Nosyk","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ehsanul","family":"Karim","sequence":"additional","affiliation":[{"name":"School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"2025072221103091000_15.7.e098318.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32229-9"},{"key":"2025072221103091000_15.7.e098318.2","unstructured":"Federal, provincial, and territorial special advisory committee on the epidemic of opioid overdoses. opioid- and stimulant-related harms in Canada. Ottawa: Public Health Agency of Canada. 2023 Available: https:\/\/health- infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/"},{"key":"2025072221103091000_15.7.e098318.3","unstructured":"British Columbia Centre on Substance Use (BCCSU) . A guideline for the clinical management of opioid use disorder. 2017. Available: http:\/\/www.bccsu.ca\/wp-content\/uploads\/2017\/06\/BC-OUD-Guidelines_June2017.pdf"},{"key":"2025072221103091000_15.7.e098318.4","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s11136-011-0027-0","article-title":"Health-related quality of life changes associated with buprenorphine treatment for opioid dependence","volume":"21","author":"Raisch","year":"2012","journal-title":"Qual Life Res"},{"key":"2025072221103091000_15.7.e098318.5","doi-asserted-by":"publisher","DOI":"10.1080\/00952990701523698"},{"key":"2025072221103091000_15.7.e098318.6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"2025072221103091000_15.7.e098318.7","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2014","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025072221103091000_15.7.e098318.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m772","article-title":"Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study","volume":"368","author":"Pearce","year":"2020","journal-title":"BMJ"},{"key":"2025072221103091000_15.7.e098318.9","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1007\/s11469-023-01098-8","article-title":"The Impact of Longitudinal Substance Use Patterns on the Risk of Opioid Agonist Therapy Discontinuation: A Repeated Measures Latent Class Analysis","volume":"22","author":"Cui","year":"2024","journal-title":"Int J Ment Health Addict"},{"key":"2025072221103091000_15.7.e098318.10","doi-asserted-by":"publisher","DOI":"10.7326\/M17-3107"},{"key":"2025072221103091000_15.7.e098318.11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025072221103091000_15.7.e098318.12","doi-asserted-by":"crossref","unstructured":"Deborah Dowell MD , Shiromani Gyawali MS , Christina Mikosz MD . Treatment for opioid use disorder: population estimates\u2014United States, 2022. 2024.","DOI":"10.15585\/mmwr.mm7325a1"},{"key":"2025072221103091000_15.7.e098318.13","doi-asserted-by":"publisher","DOI":"10.1111\/add.15087"},{"key":"2025072221103091000_15.7.e098318.14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00952990.2018.1546862","article-title":"Development of a Cascade of Care for responding to the opioid epidemic","volume":"45","author":"Williams","year":"2019","journal-title":"Am J Drug Alcohol Abuse"},{"key":"2025072221103091000_15.7.e098318.15","unstructured":"College of Physicians and Surgeons of British Columbia . Methadone maintenance program: clinical practice guideline. 2015. Available: http:\/\/www.bccdc.ca\/resource-gallery\/Documents\/Statistics%20and%20Research\/Publications\/Epid\/Other\/02_CPSBC-Methadone_Maintenance_Program_Clinical%20_Practice_Guideline.pdf"},{"key":"2025072221103091000_15.7.e098318.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-021-00535-y","article-title":"'It\u2019s like 'liquid handcuffs': The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduct J"},{"key":"2025072221103091000_15.7.e098318.17","doi-asserted-by":"crossref","first-page":"209055","DOI":"10.1016\/j.josat.2023.209055","article-title":"Transitioning off methadone: A qualitative study exploring why patients discontinue methadone treatment for opioid use disorder","volume":"150","author":"Thakrar","year":"2023","journal-title":"J Subst Use Addict Treat"},{"key":"2025072221103091000_15.7.e098318.18","unstructured":"British Columbia Centre on Substance Use (BCCSU) . A guideline for the clinical management of opioid use disorder. 2023. Available: https:\/\/www.bccsu.ca\/wp-content\/uploads\/2023\/12\/BC-OUD-Treatment-Guideline_2023-Update.pdf"},{"key":"2025072221103091000_15.7.e098318.19","doi-asserted-by":"crossref","first-page":"108799","DOI":"10.1016\/j.drugalcdep.2021.108799","article-title":"Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018","volume":"225","author":"Krebs","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025072221103091000_15.7.e098318.20","doi-asserted-by":"crossref","first-page":"108647","DOI":"10.1016\/j.jsat.2021.108647","article-title":"Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada","volume":"133","author":"Kurz","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"2025072221103091000_15.7.e098318.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.03.008"},{"key":"2025072221103091000_15.7.e098318.22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/10550880802324382","article-title":"One-year and cumulative retention as predictors of success in methadone maintenance treatment: a comparison of two clinics in the United States and Israel","volume":"27","author":"Peles","year":"2008","journal-title":"J Addict Dis"},{"key":"2025072221103091000_15.7.e098318.23","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamapsychiatry.2022.3118","article-title":"Association Between Buprenorphine Treatment Gaps, Opioid Overdose, and Health Care Spending in US Medicare Beneficiaries With Opioid Use Disorder","volume":"79","author":"Gibbons","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"2025072221103091000_15.7.e098318.24","unstructured":"Ministry of Health . New zealand practice guidelines for opioid substitution treatment. 2014."},{"key":"2025072221103091000_15.7.e098318.25","unstructured":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group . Drug misuse and dependence: UK guidelines on clinical management. London Department of Health; 2017."},{"key":"2025072221103091000_15.7.e098318.26","unstructured":"Gowing L ARDAFMLN . National guidelines for medication-assisted treatment of opioid dependence. Commonwealth of Australia; 2014."},{"key":"2025072221103091000_15.7.e098318.27","unstructured":"New South Wales Ministry of H . NSW clinical guidelines: treatment of opioid dependence - 2018. NSW Ministry of Health; 2018."},{"key":"2025072221103091000_15.7.e098318.28","unstructured":"Canadian Research Initiative in Substance Misuse . CRISM national guideline for the clinical management of opioid use disorder. Canadian Institutes on Health Research; 2018."},{"key":"2025072221103091000_15.7.e098318.29","unstructured":"Clinical Guidelines on Drug Misuse and Dependence, Update 2017 Independent Expert Working Group . Drug misuse and dependence: UK guidelines on clinical management. Global and Public Health\/ Population Health\/ Healthy Behaviours; 2017."},{"key":"2025072221103091000_15.7.e098318.30","unstructured":"Centre for Addiction and Mental Health . Opioid agonist therapy: a synthesis of canadian guidelines for treating opioid use disorder. 2021. Available: www.camh.ca"},{"key":"2025072221103091000_15.7.e098318.31","unstructured":"Queensland opioid dependence treatment guidelines 2023. The State of Queensland (Queensland Health). 2023 Available: https:\/\/www.health.qld.gov.au\/__data\/assets\/pdf_file\/0024\/1246605\/Queensland-Opioid-Dependence-Treatment-Guidelines-2023.pdf"},{"key":"2025072221103091000_15.7.e098318.32","unstructured":"Bromley L KMRLSAWJ . Methadone treatment for people who use fentanyl: recommendations. Toronto, ON: META:PHI. 2021 Available: https:\/\/www.metaphi.ca\/"},{"key":"2025072221103091000_15.7.e098318.33","unstructured":"British Columbia Centre on Substance Use . A guideline for the clinical management of opioid use disorder. 2023."},{"key":"2025072221103091000_15.7.e098318.34","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000166"},{"key":"2025072221103091000_15.7.e098318.35","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000668"},{"key":"2025072221103091000_15.7.e098318.36","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.ADM.0000435321.39251.d7","article-title":"Safe Methadone Induction and Stabilization","volume":"7","author":"Baxter","year":"2013","journal-title":"J Addict Med"},{"key":"2025072221103091000_15.7.e098318.37","unstructured":"California Bridge Program . Methadone hospital quick start. 2019. Available: https:\/\/www.bridgetotreatment.org\/resources"},{"key":"2025072221103091000_15.7.e098318.38","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/ajad.12288","article-title":"Treatment outcomes in opioid dependent patients with different buprenorphine\/naloxone induction dosing patterns and trajectories","volume":"24","author":"Jacobs","year":"2015","journal-title":"Am J Addict"},{"key":"2025072221103091000_15.7.e098318.39","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2009.10400539"},{"key":"2025072221103091000_15.7.e098318.40","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","article-title":"Leaving buprenorphine treatment: patients\u2019 reasons for cessation of care","volume":"46","author":"Gryczynski","year":"2014","journal-title":"J Subst Abuse Treat"},{"key":"2025072221103091000_15.7.e098318.41","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/JAN.0000000000000307","article-title":"Perceptions and Experiences of Methadone Maintenance Treatment","volume":"30","author":"Jeske","year":"2019","journal-title":"UJAN"},{"key":"2025072221103091000_15.7.e098318.42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/02791072.2011.587392","article-title":"Redefining retention: recovery from the patient\u2019s perspective","volume":"43","author":"Mitchell","year":"2011","journal-title":"J Psychoactive Drugs"},{"key":"2025072221103091000_15.7.e098318.43","doi-asserted-by":"publisher","DOI":"10.1111\/add.13789"},{"key":"2025072221103091000_15.7.e098318.44","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21383"},{"key":"2025072221103091000_15.7.e098318.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2113319"},{"key":"2025072221103091000_15.7.e098318.46","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"2025072221103091000_15.7.e098318.47","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3182114039"},{"key":"2025072221103091000_15.7.e098318.48","unstructured":"BC Ministry of Health . PharmaNet. British Columbia Ministry of Health [publisher]. Data Extract. MOH; 2018. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025072221103091000_15.7.e098318.49","unstructured":"BC Ministry of Health . Discharge abstract database (hospital separations). British Columbia Ministry of Health [Publisher] Data Extract MOH; 2018. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025072221103091000_15.7.e098318.50","unstructured":"BC Ministry of Health . Medical services plan (msp) payment information file. British Columbia Ministry of Health [Publisher] Data Extract MOH; 2018. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025072221103091000_15.7.e098318.51","unstructured":"BC Vital Statistics Agency . Vital statistics deaths. British Columbia Ministry of Health [Publisher] Data Extract MOH; 2018. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025072221103091000_15.7.e098318.52","unstructured":"Ministry of Public Safety and Solicitor General (PSSG) . BC corrections dataset. British Columbia Ministry of Health [Publisher] Data Extract MOH; 2018. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025072221103091000_15.7.e098318.53","unstructured":"Perinatal Services BC . British columbia perinatal data registry. British Columbia Ministry of Health [Publisher] Data Extract MOH; 2018. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025072221103091000_15.7.e098318.54","unstructured":"BC Ministry of Health . National ambulatory care reporting system (nacrs). British Columbia Ministry of Health [Publisher] Data Extract MOH; 2018. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025072221103091000_15.7.e098318.55","unstructured":"British Columbia Ministry of Health . Data from: client roster. British Columbia Ministry of Health [Publisher] Data Extract MOH; 2022. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025072221103091000_15.7.e098318.56","unstructured":"British Columbia Ministry of Social Development and Poverty Reduction . Social development and poverty reduction database (SDPR). British Columbia Ministry of Health [Publisher] Data Extract MOH; 2020. Available: http:\/\/www.health.gov.bc.ca\/data"},{"key":"2025072221103091000_15.7.e098318.57","unstructured":"Government of British Columbia . Personal health identification. 2018 Available: https:\/\/www2.gov.bc.ca\/gov\/content\/health\/health-drug-coverage\/msp\/bc-residents\/personal-health-identification"},{"key":"2025072221103091000_15.7.e098318.58","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/add.15737","article-title":"Opioid agonist treatment uptake within provincial correctional facilities in British Columbia, Canada","volume":"117","author":"Kurz","year":"2022","journal-title":"Addiction"},{"key":"2025072221103091000_15.7.e098318.59","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036102","article-title":"Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada","volume":"10","author":"Piske","year":"2020","journal-title":"BMJ Open"},{"key":"2025072221103091000_15.7.e098318.60","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-068729","article-title":"Comparative effectiveness of urine drug screening strategies alongside opioid agonist treatment in British Columbia, Canada: a population-based observational study protocol","volume":"13","author":"Guerra-Alejos","year":"2023","journal-title":"BMJ Open"},{"key":"2025072221103091000_15.7.e098318.61","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-019-00494-6"},{"key":"2025072221103091000_15.7.e098318.62","doi-asserted-by":"publisher","DOI":"10.1177\/0962280211403603"},{"key":"2025072221103091000_15.7.e098318.63","doi-asserted-by":"crossref","unstructured":"Limozin JM , Seaman SR , Su L . Inference procedures in sequential trial emulation with survival outcomes: Comparing confidence intervals based on the sandwich variance estimator, bootstrap and jackknife. arXiv[pre-print] 2024. doi:10.1177\/09622802251356594","DOI":"10.1177\/09622802251356594"},{"key":"2025072221103091000_15.7.e098318.64","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181df1b69"},{"key":"2025072221103091000_15.7.e098318.65","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000581"},{"key":"2025072221103091000_15.7.e098318.66","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3"},{"key":"2025072221103091000_15.7.e098318.67","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/EDE.0000000000000787","article-title":"Can We Train Machine Learning Methods to Outperform the High-dimensional Propensity Score Algorithm?","volume":"29","author":"Karim","year":"2018","journal-title":"Epidemiology"},{"key":"2025072221103091000_15.7.e098318.68","doi-asserted-by":"publisher","DOI":"10.1097\/01.ede.0000222409.00878.37"},{"key":"2025072221103091000_15.7.e098318.69","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e31828d0590"},{"key":"2025072221103091000_15.7.e098318.70","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e31828abafb"},{"key":"2025072221103091000_15.7.e098318.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.006"},{"key":"2025072221103091000_15.7.e098318.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.06.006"},{"key":"2025072221103091000_15.7.e098318.73","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/EDE.0000000000001697","article-title":"Comparative Analysis of Instrumental Variables on the Assignment of Buprenorphine\/Naloxone or Methadone for the Treatment of Opioid Use Disorder","volume":"35","author":"Homayra","year":"2024","journal-title":"Epidemiology"},{"key":"2025072221103091000_15.7.e098318.74","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000279"},{"key":"2025072221103091000_15.7.e098318.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2007.09.009"},{"key":"2025072221103091000_15.7.e098318.76","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/biom.13792","article-title":"Instrumental variable estimation of the causal hazard ratio","volume":"79","author":"Wang","year":"2023","journal-title":"Biometrics"},{"key":"2025072221103091000_15.7.e098318.77","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.drugpo.2018.06.003","article-title":"Developing a patient-reported experience questionnaire with and for people who use drugs: A community engagement process in Vancouver\u2019s Downtown Eastside","volume":"59","author":"Olding","year":"2018","journal-title":"International Journal of Drug Policy"},{"key":"2025072221103091000_15.7.e098318.78","unstructured":"Canadian Institutes of Health Research NS and ERC of C and SS and HRC . Tri-council policy statement: ethical conduct for research involving humans. Canada; 2018."},{"key":"2025072221103091000_15.7.e098318.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2025072221103091000_15.7.e098318.80","unstructured":"World Health O . World health organization model list of essential medicines - 22nd list. World Health Organization; 2021."},{"key":"2025072221103091000_15.7.e098318.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.03.012"},{"key":"2025072221103091000_15.7.e098318.82","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/Naloxone vs Methadone for the Treatment of Opioid Use Disorder","volume":"332","author":"Nosyk","year":"2024","journal-title":"JAMA"},{"key":"2025072221103091000_15.7.e098318.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2018.09.001"},{"key":"2025072221103091000_15.7.e098318.84","unstructured":"The national overall count from January 2016 to June 2023 includes deaths from British Columbia (2019 to 2023 [Jan to Jun]) related to all illicit drugs and Quebec (2021 to 2023 [Jan to Jun]) related to drug or opioid-related intoxication. 2019."},{"key":"2025072221103091000_15.7.e098318.85","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-017-0287-2"},{"key":"2025072221103091000_15.7.e098318.86","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/ADM.0000000000000156","article-title":"Evaluating the Effectiveness of First-Time Methadone Maintenance Therapy Across Northern, Rural, and Urban Regions of Ontario, Canada","volume":"9","author":"Eibl","year":"2015","journal-title":"J Addict Med"},{"key":"2025072221103091000_15.7.e098318.87","unstructured":"Characteristics of patients with repeat emergency department visits for opioid-related harms in alberta, ontario and the yukon. 2024 Available: https:\/\/www.canada.ca\/en\/health-canada\/services\/opioids\/data-surveillance-research.html"},{"key":"2025072221103091000_15.7.e098318.88","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1080\/01621459.2023.2205060","article-title":"Inference for treatment-specific survival curves using machine learning","volume":"119","author":"Westling","year":"2024","journal-title":"J Am Stat Assoc"},{"key":"2025072221103091000_15.7.e098318.89","unstructured":"Polley EC , Laan MS . Super Learner Prediction: R Package, version 2.0-21. 2017 Available: https:\/\/github.com\/ecpolley\/SuperLearner"},{"key":"2025072221103091000_15.7.e098318.90","unstructured":"Westling T . SurvSuperLearner: super learning for conditional survival functions with right-censored data. 2024 Available: https:\/\/github.com\/tedwestling\/survSuperLearner"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-098318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T17:40:16Z","timestamp":1753292416000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-098318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":90,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,22]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2024-098318"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098318","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}